CTLA4 and melanoma: Superior therapeutic efficacy with combination immune checkpoint blockade was demonstrated in clinical trials of anti-PD-1 and anti-CTLA-4 for melanoma including improved long-term survival but at a cost of higher rates of immune-related toxicities.71